Amgen Jumps as Migraine Drug Wows in Late-Stage Study Post author:Sam Post published:January 22, 2018 Post category:BioPharma Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. Source: BioSpace You Might Also Like FDA Shuts Down Addiction Study After Monkey Deaths January 28, 2018 Argos Cuts Staff by 38% After Devastating Phase III News March 9, 2017 Cannabis Company GW Pharmaceuticals’ Seizure Drug Flunks Phase II Trial February 21, 2018